TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a neutral rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st.

TRACON Pharmaceuticals Stock Performance

Shares of TCON stock opened at $0.15 on Friday. The company has a market capitalization of $504,339.00, a price-to-earnings ratio of 0.22 and a beta of 1.29. TRACON Pharmaceuticals has a one year low of $0.00 and a one year high of $14.75. The company’s 50-day moving average is $0.59 and its 200 day moving average is $2.48.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The firm had revenue of $0.06 million for the quarter.

TRACON Pharmaceuticals Dividend Announcement

The business also recently declared a dividend, which was paid on Monday, July 8th. Stockholders of record on Friday, June 28th were paid a $0.045 dividend. The ex-dividend date was Thursday, June 27th. This represents a dividend yield of 40.3%.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.